DMT
Disease-Modifying Therapy
Thursday, June 2, 2022: 5:00 PM-7:00 PM
Prince George's Exhibit Hall (Gaylord National Resort & Convention Center)
Prognostic Value of the Magnims Score for Assessment of Disease Modifying Therapy in Patients with Relapsing Multiple Sclerosis Treated with Ponesimod
Alexander Keenan, MA, MHP, Janssen Scientific Affairs, LLC;
Kavita Gandhi, MS, Janssen Global Market Access, LLC;
Hoa H. Le, PhD, Janssen Scientific Affairs, LLC;
Ibrahim Turkoz, PhD, Janssen Research & Development, LLC;
Shien Guo, PhD, Evidera;
Weiqin Liao, MPH, MS, Evidera;
Christopher Pelligra, MSc, Evidera
Estimated Prevalence of First-Dose Cardiac Observation in Patients Taking Ponesimod
David M. Kern, PhD, Janssen Research & Development, LLC;
Hoa H. Le, PhD, Janssen Scientific Affairs, LLC;
Maria Ait-Tihyaty, PhD, Janssen Global Medical Affairs, LLC;
Alexander Keenan, MA, MHP, Janssen Scientific Affairs, LLC
Ponesimod Demonstrated Increased Clinical Benefit over Teriflunomide in Early Disease Subgroup Compared with Overall Population
Allitia DiBernardo, MD, Janssen Research & Development, LLC;
Ibrahim Turkoz, PhD, Janssen Research & Development, LLC;
Michael Kutch, MS, Janssen Research & Development, LLC;
Maria Ait-Tihyaty, PhD, Janssen Research & Development, LLC
Characterizing Early Real-World Experience of Narcoms Registry Participants Treated with Diroximel Fumarate
Amber Salter, PhD, University of Texas Southwestern Medical Center;
Samantha Lancia, MS, UT Southwestern Medical Center;
Ruth Ann Marrie, MD, PhD, University of Manitoba;
Gary R Cutter, PhD, University of Alabama at Birmingham;
Robert J Fox, MD, Mellen Center for Treatment and Research in Multiple Sclerosis, Cleveland Clinic;
Sarah M England, PhD, Biogen;
Shivani Kapadia, PharmD, RPh, Biogen;
Sai L Shankar, PhD, Biogen;
James B Lewin, PharmD, Biogen
Effect of Ofatumumab on Lymphocytes and Neutrophils in Patients with Relapsing Multiple Sclerosis over 4 Years
Amit Bar-Or, MD, Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania;
Kevin Winthrop, MD, MPH, Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University;
Heinz Wiendl, MD, MPH, University of Muenster;
David Paling, MB ChB, MRCP, PhD, Department of Neurology, Royal Hallamshire Hospital;
Tobias Sejbaek, MD, PhD, Department of Neurology, Hospital Southwest Jutland, University Hospital of Southern Denmark, Department of Regional Health Research, University of Southern Denmark;
Carlo Pozzilli, MD, PhD, Department of Human Neuroscience, La Sapienza University;
Celine Louapre, MD, PhD, Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225;
Wendy Su, PhD, Novartis Pharmaceuticals Corporation;
Virginia DeLasHeras, MD, Novartis Pharma AG;
Ronald Zielman, MD, PhD, Novartis Pharma B.V.;
Roseanne Sullivan, PharmD, Novartis Pharmaceuticals Corporation;
Ayan Das Gupta, MSc, Novartis Healthcare Pvt. Ltd;
Xixi Hu, PhD, Novartis Pharmaceuticals Corporation;
Anne H. Cross, MD, Washington University in St. Louis
Evaluating Humoral Immune Response to mRNA COVID-19 Vaccines in Siponimod-Treated Patients with Advancing Forms of RMS: A COVID-19 Vaccine Sub-Study of the Exchange Trial
Amit Bar-Or, MD, Perelman School of Medicine, University of Pennsylvania;
Yang Mao-Draayer, MD, PhD, Autoimmunity Center of Excellence, Multiple Sclerosis Center, University of Michigan;
Silvia R Delgado, MD, University of Miami Miller School of Medicine;
Robert J Fox, MD, Cleveland Clinic;
Linda-Ali Cruz, MD, Novartis Pharmaceuticals Corporation;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Gina Mavrikis Cox, PhD, Novartis Pharmaceuticals Corporation;
Stanley L Cohan, MD, PhD, Providence Brain Institute
Long-Term Efficacy and Safety, Including COVID-19 Outcomes, Among Ozanimod-Treated Patients with Relapsing Multiple Sclerosis in the Daybreak Open-Label Extension Trial
Bruce A.C. Cree, MD, Weill Institute for Neurosciences, University of California San Francisco;
Krzysztof W. Selmaj, MD, Center for Neurology, Łódź, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury;
Lawrence Steinman, MD, Beckman Center for Molecular Medicine, Stanford University Medical Center;
Giancarlo Comi, MD, Vita-Salute San Raffaele University and Casa di Cura del Policlinico;
Amit Bar-Or, MD, Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University, and NeuroRx Research;
Hans-Peter Hartung, MD, Heinrich-Heine University, University of Sydney, Medical University of Vienna, Palacky University Olomouc;
Xavier Montalban, MD, PhD, Hospital Universitari Vall d’Hebron;
Eva K Havrdova, MD, PhD, Charles University;
James K. Sheffield, MD, MBA, MS, Bristol Myers Squibb;
Neil Minton, MD FFPM, Bristol Myers Squibb;
Chun-Yen Cheng, PhD, Bristol Myers Squibb;
Diego Silva, MD, Bristol Myers Squibb;
Ludwig Kappos, MD, Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel;
Jeffrey A Cohen, MD, Mellen MS Center, Cleveland Clinic
Patient Characteristics and Treatment Patterns Prior to Initiating Cladribine Tablets: A US Retrospective Commercial Claims Analysis
Chris M Kozma, PhD, CK Consulting Associates, LLC;
Emily Evans, MD, MBE, EMD Serono;
Lori A Lebson, PhD, EMD Serono;
Amy L Phillips, PharmD, EMD Serono;
Carroline Lobo, PhD, EMD Serono
Effects of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions: An Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis
Douglas L Arnold, MD, NeuroRx Research;
Colm Elliott, MD, NeuroRx Research;
Xavier Montalban, MD PhD, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron;
Emily C Martin, PhD, EMD Serono;
Yann Hyvert, PhD, The healthcare business of Merck KGaA;
Davorka Tomic, PhD, The healthcare business of Merck KGaA
Evobrutinib Significantly Reduces Relapses and MRI Outcomes in Patients with Multiple Sclerosis: Association with Baseline Neurofilament Light Chain Levels
Jens Kuhle, MD PhD, University Hospital Basel, and University of Basel;
Ludwig Kappos, MD, University Hospital Basel, and University of Basel;
Xavier Montalban, MD PhD, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron;
Ying Li, MS, EMD Serono;
Karthinathan Thangavelu, PhD, EMD Serono;
Yann Hyvert, PhD, The healthcare business of Merck KGaA;
Davorka Tomic, PhD, The healthcare business of Merck KGaA
Improved Cognitive Processing Speed with Ublituximab in Patients with Highly Active Relapsing Multiple Sclerosis
Derrick Robertson, MD, University of South Florida;
Lawrence Steinman, MD, Beckman Center for Molecular Medicine, Stanford University Medical Center;
Edward J Fox, MD, PhD, Central Texas Neurology Consultants;
Hans-Peter Hartung, MD, Heinrich Heine University, Medical University of Vienna, Brain and Mind Centre, University of Sydney, Palacky University;
Enrique Alvarez, MD, PhD, University of Colorado;
Peiqing Qian, MD, Swedish Medical Center;
Sibyl Wray, MD, Hope Neurology MS center;
DeRen Huang, MD, PhD, Mount Carmel Health System;
Krysztof Selmaj, MD, PhD, Center of Neurology, University of Warmia & Mazury;
Daniel Wynn, MD, Consultants in Neurology MS Center;
Koby Mok, PhD, TG Therapeutics;
Christopher A Garner, PA-C, TG Therapeutics Inc;
Bruce A Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco
Longer-Term Effects of Ofatumumab on Clinical and MRI Outcomes in Patients with Relapsing Multiple Sclerosis
Derrick Robertson, MD, University of South Florida;
Stephen L Hauser, PhD, UCSF Weill Institute for Neurosciences, University of California;
Edward J Fox, MD, PhD, University of Texas Medical Branch;
Ludwig Kappos, MD, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel;
Jeffrey A Cohen, MD, Mellen MS Center, Cleveland Clinic;
Angela Aungst, MPH, Multiple Sclerosis Division Department of Neurology University of South Florida;
Wendy Su, PhD, Novartis Pharmaceuticals Corporation;
Ronald Zielman, MD, PhD, Novartis Pharma B.V.;
Jing Xi, PhD, China Novartis Institutes For Biomedical Research Co., Ltd.;
Ayan Das Gupta, MSc, Novartis Healthcare Pvt. Ltd.;
Dee Stoneman, MPharm, Novartis Pharma AG
Development and Interrelation of Spatiotemporal Patterns of Brain Atrophy and Lesions in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study
Giordano Gentile, MSc, University of Siena, SIENA imaging SRL;
Rozemarijn Mattiesing, MSc, MS Center Amsterdam;
Iman Brouwer, MASc, MS Center Amsterdam;
Dominic Jack, PhD, Merck Serono Ltd, Feltham, UK, an affiliate of Merck KGaA, Darmstadt, Germany;
Frederik Barkhof, MD, PhD, MS Center Amsterdam, UCL London;
Nicola De Stefano, MD, PhD, University of Siena;
Bernard MJ Uitdehaag, MD, PhD, MS Center Amsterdam;
Hugo Vrenken, PhD, MS Center Amsterdam;
Marco Battaglini, PhD, SIENA imaging SRL, University of Siena
Development and Interrelation of Whole-Brain Atrophy and Lesion Volume in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study
Rozemarijn Mattiesing, MSc, MS Center Amsterdam;
Giordano Gentile, MSc, University of Siena, SIENA imaging SRL;
Iman Brouwer, MASc, MS Center Amsterdam;
Dominic Jack, PhD, Merck Serono Ltd, Feltham, UK, an affiliate of Merck KGaA, Darmstadt, Germany;
Frederik Barkhof, MD, PhD, MS Center Amsterdam, UCL London;
Nicola De Stefano, MD, PhD, University of Siena;
Bernard MJ Uitdehaag, MD, PhD, MS Center Amsterdam;
Jos WR Twisk, PhD, Amsterdam UMC;
Marco Battaglini, PhD, SIENA imaging SRL, University of Siena;
Hugo Vrenken, PhD, MS Center Amsterdam
Infusion-Related Reactions with Ublituximab in the Phase 3 Ultimate I and II Studies in Relapsing Multiple Sclerosis
Edward J Fox, MD, PhD, Central Texas Neurology Consultants;
Lawrence Steinman, MD, Beckman Center for Molecular Medicine, Stanford University Medical Center;
Hans-Peter Hartung, MD, Heinrich Heine University, Medical University of Vienna, Palacky University, Brain and Mind Centre, University of Sydney;
Enrique Alvarez, MD, PhD, University of Colorado;
Peiqing Qian, MD, Swedish Medical Center;
Sibyl Wray, MD, Hope Neurology MS center;
Derrick Robertson, MD, University of South Florida;
DeRen Huang, MD, PhD, Mount Carmel Health System;
Krysztof Selmaj, MD, PhD, Center of Neurology, University of Warmia & Mazury;
Daniel Wynn, MD, Consultants in Neurology MS Center;
Koby Mok, PhD, TG Therapeutics;
Denise Campagnolo, MD, TG Therapeutics Inc;
Bruce A Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco
Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Five Data
Elizabeth A Douglas, MPH, The Elliot Lewis Center for Multiple Sclerosis Care;
Isabella O'Shea, B.S., The Elliot Lewis Center for Multiple Sclerosis Care;
Andrew J Bouley, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Ellen S Lathi, M.D., The Elliot Lewis Center for Multiple Sclerosis Care
Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Five Data
Elizabeth A Douglas, MPH, The Elliot Lewis Center for Multiple Sclerosis Care;
Isabella O'Shea, B.S., The Elliot Lewis Center for Multiple Sclerosis Care;
Andrew J Bouley, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care;
Ellen S Lathi, M.D., The Elliot Lewis Center for Multiple Sclerosis Care
Adherence to Dmts in Patients with Multiple Sclerosis across Health-System Specialty Pharmacies
Abbi Blevins, PharmD, MBA, CSP, WVUMedicine;
Evan Turco, PharmD, WVUMedicine;
Autumn D. Zuckerman, PharmD, BCPS, AAHIVP, CSP, Vanderbilt University Medical Center;
Aimee Banks, PharmD, BCPS, MSCS, Vanderbilt University Medical Center;
Julie Wawrzyniak, PharmD, BCACP, MSCS, UR Medicine;
Elizabeth Rightmier, PharmD, BCPS, MSCS, UR Medicine;
Alicia Zagel, PhD, MPH, Fairview Pharmacy Services;
Dana Simonson, PharmD, BCPS, Fairview Pharmacy Services;
Josh DeClercq, MS, Vanderbilt University Medical Center;
Leena Choi, PhD, Vanderbilt University Medical Center
Sostos Study Design: Assessing Transition to Ofatumumab from Other Disease-Modifying Therapies in RRMS after Elevation of Serum Neurofilament Light Levels
Gina Mavrikis Cox, PhD, Novartis Pharmaceuticals Corporation;
Jeffrey A Cohen, MD, Cleveland Clinic Mellen Center;
Harald Kropshofer, PhD, Novartis Pharma AG;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
James Stankiewicz, MD, Novartis Pharmaceuticals Corporation
Cladribine Tablets: Collaborative Study to Evaluate the Impact on Central Nervous System Biomarkers in Multiple Sclerosis (CLOCK-MS) – Current Baseline Characteristics
Gregory F Wu, MD, PhD, Washington University in St. Louis;
Claudia Cantoni, PhD, Washington University in St. Louis;
Amber Salter, PhD, University of Texas Southwestern Medical Center;
Kenneth Lee, BA, Washington University in St. Louis;
Olaf Stuve, MD, PhD, University of Texas Southwestern Medical Center;
Amit Bar-Or, MD, Perelman School of Medicine, University of Pennsylvania;
Gabriel Pardo, MD, FAAN, Oklahoma Medical Research Foundation;
Ursula Boschert, PhD, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany;
Brooke Hayward, SM, MBA, EMD Serono;
Julie Korich, PhD, EMD Serono;
Lori A Lebson, PhD, EMD Serono;
Anne H. Cross, MD, Washington University in St. Louis
Cladribine Tablets after Treatment with Natalizumab (CLADRINA) Trial – Interim Analyses
Jeffrey Kaplan, MD, Kansas City Multiple Sclerosis and Headache Center;
Annette Okai, MD, North Texas Institute of Neurology & Headache;
Peter Sguigna, MD, University of Texas Southwestern Medical Center;
Kyle Blackburn, MD, University of Texas Southwestern Medical Center;
Lauren Tardo, MD, University of Texas Southwestern Medical Center;
Brooke Hayward, SM, MBA, EMD Serono;
Ursula Boschert, PhD, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany;
Lori A Lebson, PhD, EMD Serono;
Julie Korich, PhD, EMD Serono;
Navid Manouchehri, MD, University of Texas Southwestern Medical Center;
Rehana Z Hussain, MSc, University of Texas Southwestern Medical Center;
Olaf Stuve, MD, PhD, University of Texas Southwestern Medical Center, VA North Texas Health Care System
Baseline Demographics, Disease Characteristics, and Clinical Measures of Patients with Relapsing MS in Enlighten: A Phase 3b Study of Ozanimod on Cognitive Processing Speed
John DeLuca, PhD, Kessler Foundation, Rutgers - New Jersey Medical School;
Jon V. Riolo, PhD, Bristol Myers Squibb;
Chun-Yen Cheng, PhD, Bristol Myers Squibb;
Robert T. Naismith, MD, Washington University School of Medicine;
Sybil Wray, MD, Hope Neurology;
Ann Bass, MD, Neurology Center of San Antonio;
Edward J Fox, MD, PhD, Central Texas Neurology Consultants;
Emily Riser, MD, Alabama Neurology Associates;
Diego Silva, MD, Bristol Myers Squibb;
Robert Zivadinov, MD, Buffalo Neuroimaging Analysis Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York
Injection-Related Reactions with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Data from Clinical Studies and Post Marketing Experience
John Kramer, PA-C, St. Thomas Medical Partners-Neurology;
Patrick Vermersch, MD, PhD, Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise;
Roseanne Sullivan, PharmD, Novartis Pharmaceuticals Corporation;
Ronald Zielman, MD, PhD, Novartis Pharma B.V.;
Xixi Hu, PhD, Novartis Pharmaceuticals Corporation;
Ayan Das Gupta, MSc, Novartis Healthcare Pvt. Ltd;
Wendy Su, PhD, Novartis Pharmaceuticals Corporation;
Dee Stoneman, MPharm, Novartis Pharma AG;
Elisabeth B Lucassen, MD, Novartis Pharmaceuticals Corporation;
Olaf Hoffmann, PD Dr. med., Department of Neurology, Alexianer St. Josefs Hospital
The Effect of Ocrelizumab on JC Virus Antibody Index
Joseph R Berger, MD, FACP, FAAN, FANA, Perelman School of Medicine, University of Pennsylvania;
Dina Jacobs, MD, University of Pennsylvania;
James Wilson, BA, University of Pennsylvania;
Emma Wilson, None, University of Pennsylvania;
Akash Virupakshaiah, MD, University of Pennsylvania;
David Do, MD, University of Pennsylvania
Pregnancy Outcomes in Ofatumumab-Treated Patients with Multiple Sclerosis
Kerstin Hellwig, MD, St Josef Hospital, Ruhr University;
Bassem Yamout, MD, Harley Street Medical Center;
Riley Bove, MD, University of California San Francisco;
Krishna Swetha Gummuluri, MBBS, Dip. Pharm. Med, Novartis Healthcare Pvt. Ltd.;
Ulf Schulze Topphoff, PhD, Novartis Pharma GmbH;
Simone Fantaccini, MD, Novartis Pharma A.G.;
Ronald Zielman, MD, PhD, Novartis Pharma B.V.;
Roseanne Sullivan, PharmD, Novartis Pharmaceuticals Corporation;
Maria Pia Amato, MD, University of Florence, IRCCS Fondazione Don Carlo Gnocchi;
Ruth Dobson, PhD, FRCP, Royal London Hospital, BartsHealth NHS Trust, Wolfson Institute of Preventive Medicine, Queen Mary University of London;
Maria Houtchens, MD, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School
COVID-19 Outcomes and Vaccination Status in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab
Kevin Winthrop, MD, MPH, Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University;
Silvia Delgado, MD, University of Miami Miller School of Medicine;
Mario Habek, MD, University Hospital Center Zagreb, University of Zagreb, School of Medicine;
Maria Davydovskaya, PhD, Moscow state Public Healthcare InszCity Clinical Hospital 24;
Brian Ward, MD, Infectious Diseases Division, Research Institute of the McGill University Health Centre;
Bruce A. C. Cree, MD, PhD, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, California, USA;
Natalia Totolyan, MD, First Saint Petersburg State Medical University;
Linda Mancione, BA, Novartis Pharmaceuticals Corporation;
Roseanne Sullivan, PharmD, Novartis Pharmaceuticals Corporation;
Ronald Zielman, MD, PhD, Novartis Pharma B.V.;
Xixi Hu, PhD, Novartis Pharmaceuticals Corporation;
Ayan Das Gupta, MSc, Novartis Healthcare Pvt. Ltd;
Xavier Montalban, MD PhD, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron;
Anne Cross, MD, Washington University School of Medicine, Saint Louis
Nurown (MSC-NTF Cells) Phase 2 Clinical Trial in Progressive MS: Effects on Monocular and Bionocular Low Contrast Letter Acuity (LCLA) Outcomes
Laura Balcer, MD, MSCE, New York University Langone Medical Center;
Jeffrey A Cohen, MD, Mellen MS Center, Cleveland Clinic;
Fred D. Lublin, MD, Corinne Goldsmith Dickinson Center for Multiple Sclerosis;
Christopher B. Lock, MD, PhD, Stanford School of Medicine;
Daniel Pelletier, MD, Keck School of Medicine of University of Southern California;
Tanuja Chitnis, MD, Harvard Medical School;
Munish Mehra, PhD, Tigermed;
Yael Gothelf, Ph.D., Brainstorm Cell Therapeutics;
Revital Aricha, PhD, Brainstorm Cell Therapeutics;
Stacy Lindborg, PhD, Brainstorm Cell Therapeutics;
Chaim Lebovits, CEO, Brainstorm Cell Therapeutics;
Ralph Kern, MD, MHSc, Brainstorm Cell Therapeutics
Analysis of Post-Treatment Relapse Activity in the Phase 3 Optimum Study of Ponesimod Compared with Teriflunomide
Ludwig Kappos, MD, University Hospital Basel, and University of Basel;
Robert J Fox, MD, Mellen Center for Treatment and Research in Multiple Sclerosis, Cleveland Clinic;
Michel Burcklen, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Mark S Freedman, MSc, MD, University of Ottawa;
Brian Hennessy, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Antoine Stos, MSc, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Philippe Linscheid, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies of Johnson & Johnson;
Andrea Vaclavkova, MD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Hilke Kracker, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Tatiana Sidorenko, MD, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies of Johnson & Johnson;
Carlo Pozzilli, MD, PhD, Department of Human Neuroscience, La Sapienza University
Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial
Mali Coray, PhD, University Hospital Basel and University of Basel;
Andrea Seitzinger, PhD, the healthcare business of Merck KGaA;
Sanjeev Roy, MD, Ares Trading S.A;
Mark S Freedman, MSc, MD, University of Ottawa;
Frederik Barkhof, MD, PhD, MS Center Amsterdam, UCL Institute of Neurology;
Giancarlo Comi, MD, Università Vita-Salute San Raffaele;
Nicola De Stefano, MD, PhD, University of Siena;
Ludwig Kappos, PhD, Research Center for Clinical Neuroimmunology and Neuroscience, University Hospital Basel, University of Basel;
Jens Kuhle, MD, PhD, University Hospital Basel and University of Basel, Research Center for Clinical Neuroimmunology and Neuroscience;
Matthias Mehling, PhD, University Hospital Basel and University of Basel, Research Center for Clinical Neuroimmunology and Neuroscience
Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
Mark S Freedman, MSc, MD, University of Ottawa;
Milorad Todorović, PhD, the healthcare business of Merck KGaA;
Zuzana Murgašová, MD, Merck spol. s r.o., an affiliate of Merck KGaA, Darmstadt, Germany;
Dominic Jack, PhD, Merck Serono Ltd, Feltham, UK, an affiliate of Merck KGaA, Darmstadt, Germany
Immune Response to COVID-19 Vaccine in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy
Aliya Jaber, BS, RWJ Barnabas Health;
Meera Patel, BS, RWJ Barnabas Health;
Andrew Sylvester, MD, RWJ Barnabas Health;
Mary Yarussi, BSN, RWJ Barnabas Health;
J. Tamar Kalina, PhD, Biogen;
Jason P Mendoza, PhD, Biogen;
Robin L. Avila, PhD, Biogen;
Matthew A Tremblay, MD, Ph.D, RWJ Barnabas Health
Fetal Exposure with Ponesimod Treatment across Clinical Development Studies
Mauricio Rosas-Ballina, MD, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Annette Wooller, MS, EMEA Medical Affairs, Janssen-Cilag;
Robyn Jones, MD, Johnson & Johnson;
Andrea Vaclavkova, MD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Eva K Havrdova, MD, PhD, Charles University in Prague
Ponesimod in Relapsing Forms of Multiple Sclerosis - Long-Term Pooled Safety Results from the Clinical Development Program
Mauricio Rosas-Ballina, MD, PhD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Annette Wooller, MS, EMEA Medical Affairs, Janssen-Cilag;
Verena Walter, MS, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Maria Ait-Tihyaty, PhD, Janssen Research & Development, LLC;
Andrea Vaclavkova, MD, Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies;
Carlo Pozzilli, MD, PhD, Department of Human Neuroscience, La Sapienza University
Patient Experience on Diroximel Fumarate (DRF) from the Mymsteam Social Network: Considerations for Dmt Selection
Meghan Garabedian, CRNP, MSN, MSCN, Penn Neuroscience Center, Perelmen Center for Advanced Medicine;
Cortnee Roman, MSN, FNP-BC, Rocky Mountain Multiple Sclerosis Clinic and Research Group;
Denise R Bruen, MSN, University of Virginia Neuroscience;
Kevin Benny, BS, MyMSTeam;
Elizabeth Luce, BS, MBA, MyHealthTeam;
Beth Schneider, PhD, MyMSTeam;
Shivani Kapadia, PharmD, RPh, Biogen;
Jason P Mendoza, PhD, Biogen;
James B Lewin, PharmD, Biogen;
Mary Zhang, PharmD, Biogen;
Sai L Shankar, PhD, Biogen
Therapy Transition from Fingolimod to Oral Cladribine: Eliminating the Washout
Michelle Maynard, PharmD, BCPS, Froedtert and the Medical College of Wisconsin;
Carmen Raschka, RN, Froedtert Hospital;
Staley Brod, MD, Medical College of Wisconsin;
Ahmed Z Obeidat, MD, Ph.D., Medical College of Wisconsin;
Sam I Hooshmand, DO, Medical College of Wisconsin
Real-World Effectiveness and Safety after 5 Years of Dimethyl Fumarate Treatment in Black/African American and Hispanic/Latino American Patients with Multiple Sclerosis in Esteem
Mitzi J Williams, MD, Joi Life Wellness Group MS Center;
Lilyana Amezcua, MD, University of Southern California;
Angel Chinea, MD, San Juan MS Center;
Stanley L Cohan, MD, PhD, Providence Brain Institute;
Annette Okai, MD, North Texas Institute of Neurology and Headache;
Darin T Okuda, MD, UT Southwestern Medical Center;
Wendy Vargas, MD, Columbia University Medical Center;
Nicholas Belviso, PhD, Biogen;
Ivan Bozin, MD, Biogen;
Xiaotong Jiang, PhD, Biogen;
James B Lewin, PharmD, Biogen;
Jennifer Lyons, MD, Biogen;
Changyu Shen, PhD, Biogen;
Sarah M England, PhD, Biogen;
Nydjie Grimes, MPH, BA, Biogen, at the time of this analysis
Ofatumumab Improves Neda-3 Likelihood in Patients with Relapsing MS Identifying As Black or African American: Subgroup Analysis of the Asclepios Studies
Mitzi J Williams, MD, Joi Life Wellness, MS Neurology Center;
Lilyana Amezcua, MD, University of Southern California;
Stanley L Cohan, MD, PhD, Providence Brain Institute;
Jeffrey A Cohen, MD, Cleveland Clinic Mellen Center;
Silvia R Delgado, MD, University of Miami Miller School of Medicine;
Le H Hua, MD, Lou Ruvo Center for Brain Health;
Elisabeth B Lucassen, MD, Novartis Pharmaceuticals Corporation;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
James Stankiewicz, MD, Novartis Pharmaceuticals Corporation
Nurown (MSC-NTF) Cells Maintain Neurotrophic and Immunomodulatory Effects with S1P Modulator Siponimod
Natalie Abramov, MSc, Brainstorm Cell Therapeutics;
Ralph Kern, MD, MHSc, Brainstorm Cell Therapeutics;
Haggai Kaspi, PhD, Brainstorm Cell Therapeutics;
Stacy Lindborg, PhD, Brainstorm Cell Therapeutics;
Yael Gothelf, Ph.D., Brainstorm Cell Therapeutics;
Chaim Lebovits, CEO, Brainstorm Cell Therapeutics;
Revital Aricha, PhD, Brainstorm Cell Therapeutics
Real-World Utilization of Ofatumumab for Treatment of Multiple Sclerosis (MS): Trends Nine Months after FDA Approval
Patricia K. Coyle, MD, Department of Neurology, Stony Brook University;
Magdaliz Gorritz, MPH, IQVIA;
Rolin L Wade, RPh, MS, IQVIA;
Zifan Zhou, MS, IQVIA;
Subhan Khalid, MS, IQVIA;
Chinmay Deshpande, PhD, BPharm, Novartis Pharmaceuticals Corporation;
Qiujun Shao, PhD, Novartis Pharmaceuticals Corporation
Impact of COVID-19 on Treatment Selection for Multiple Sclerosis
Reemal Zaheer, PharmD, Johns Hopkins Medicine (Home Care Group);
Roma Amin, PharmD, BCACP, Johns Hopkins Homecare Group;
LaTasha Riddick, PharmD, BCACP, Johns Hopkins Homecare Group;
Shuvro Roy, MD, Johns Hopkins University, Johns Hopkins University School of Medicine;
Paulina Kepczynska, PharmD Candidate 2022, Johns Hopkins Medicine (Home Care Group);
Sujin Wolff, PharmD, Johns Hopkins Medicine (Home Care Group);
Amy Nathanson, PharmD, BCACP, Johns Hopkins Homecare Group;
Scott D. Newsome, DO, MSCS, FAAN, FANA, Johns Hopkins School of Medicine, Johns Hopkins University
Identifying Signs of Progression Among People with Multiple Sclerosis (MS) Using Administrative Healthcare Claims Data
Regina Berkovich, MD, PhD, Neurology Program, Los Angeles County & USC Medical Center;
Wing Chow, PharmD, MPH, Novartis Pharmaceuticals Corporation;
Qiujun Shao, PhD, Novartis Pharmaceuticals Corporation;
Magdaliz Gorritz, MPH, IQVIA;
Zifan Zhou, MS, IQVIA;
Hsiu-Ching Chang, PhD, IQVIA;
Rolin L Wade, RPh, MS, IQVIA
Inverse Relationship between Plasma Neurofilament Light Chain Concentration and Symbol Digit Modalities Test Scores in the Sunbeam Trial of Ozanimod in RMS
Sarah Harris, PhD, Bristol Myers Squibb;
Giancarlo Comi, MD, Vita-Salute San Raffaele University and Casa di Cura del Policlinico;
Bruce A.C. Cree, MD, Weill Institute for Neurosciences, University of California San Francisco;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University, and NeuroRx Research;
Lawrence Steinman, MD, Beckman Center for Molecular Medicine, Stanford University Medical Center;
James K. Sheffield, MD, MBA, MS, Bristol Myers Squibb;
Harry Southworth, PhD, Data Clarity Consulting Ltd.;
Rachel Maddux, PhD, Bristol Myers Squibb;
Ludwig Kappos, MD, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel;
Jeffrey A Cohen, MD, Mellen MS Center, Cleveland Clinic
A Post Hoc Analysis of Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod in Phase 3 Trials
Sarah Harris, PhD, Bristol Myers Squibb;
Harry Southworth, PhD, Data Clarity Consulting Ltd.;
James K. Sheffield, MD, Bristol Myers Squibb;
Rachel Maddux, PhD, Bristol Myers Squibb;
Jeffrey A. Cohen, MD, Mellen Center for MS Treatment and Research, Cleveland Clinic
A Systematic Literature Review of Immunoglobulin Levels Among B-Cell–Depleting Therapies and Risk of Infections in Relapsing Multiple Sclerosis
Shiv Saidha, MBBCh, MD, MRCPI, Johns Hopkins School of Medicine;
Judith Bell, BS, RTI Health Solutions;
Sydney Harold, MS, RTI Health Solutions;
Jose Marcano Belisario, PhD, RTI Health Solutions;
Emma Hawe, MS, RTI Health Solutions;
Qiujun Shao, PhD, Novartis Pharmaceuticals Corporation;
Kerri Wyse, Pharm.D., CCRC, CMD, Novartis Pharmaceuticals Corporation;
Eric M. Maiese, PhD, Novartis Pharmaceuticals Corporation
Ofatumumab Improves Neda-3 Likelihood in Hispanic/Latino Patients with Relapsing Multiple Sclerosis: Subgroup Analysis of the Asclepios Studies
Silvia R Delgado, MD, University of Miami Miller School of Medicine;
Lilyana Amezcua, MD, University of Southern California;
Stanley L Cohan, MD, PhD, Providence Brain Institute;
Jeffrey A Cohen, MD, Mellen MS Center, Cleveland Clinic;
Le H Hua, MD, Lou Ruvo Center for Brain Health;
Elisabeth B Lucassen, MD, Novartis Pharmaceuticals Corporation;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Mitzi J Williams, MD, Joi Life Wellness, MS Neurology Center;
James Stankiewicz, MD, Novartis Pharmaceuticals Corporation
Diroximel Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Interim Safety and Efficacy Results from the Phase 3 Evolve-MS-1 Study
Sybil Wray, MD, Hope Neurology;
Cong Zhu, PhD, Biogen;
Barry A Singer, MD, The MS Center for Innovations in Care, Missouri Baptist Medical Center;
Jelena Drulovic, MD, PhD, University of Belgrade;
Donald Negroski, MD, MS Center of Sarasota;
Valencia Hood-Humphrey, MSc, Biogen;
Sai L Shankar, PhD, Biogen;
Seth Levin, MD, Biogen;
Shivani Kapadia, PharmD, RPh, Biogen;
Florian Then Bergh, MD, University of Leipzig
